

Preventive anti-resorptive drug administration in disuse osteoporosis might preserve trabecular connectivity

Citation for published version (APA):

Ruimerman, R., Tanck, E., Rietbergen, van, B., Hilbers, P. A. J., & Huiskes, H. W. J. (2004). *Preventive anti-resorptive drug administration in disuse osteoporosis might preserve trabecular connectivity*. Poster session presented at 14th European Society of Biomechanics Conference (ESB, 2004), 's-Hertogenbosch, Netherlands.

Document status and date:

Published: 01/01/2004

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

PREVENTIVE ANTI-RESORPTIVE DRUG ADMINISTRATION IN DISUSE OSTEOPOROSIS MIGHT PRESERVE TRABECULAR CONNECTIVITY

Ronald Ruimerman (1), Esther Tanck (2), Bert van Rietbergen (1),
Peter Hilbers (1), Rik Huiskes (1)

1. Dept. of Biomed. Eng., Eindhoven University of Technology, The Netherlands.
2. Orthop. Res. Lab., UMCN, University Nijmegen, The Netherlands

INTRODUCTION

Osteoporosis is caused by altered bone forming osteoblast and bone resorbing osteoclast activities, causing degenerated bone structure. In *disuse* osteoporosis reduced loads cause this condition. It is often treated with *anti-resorptive drugs* (ARD), which preserve bone mass and fracture resistance. We developed a theory for bone modeling and remodeling as governed by mechanical forces (Huiskes, 2000). In this work we investigated whether the theory can describe the known morphological effects of osteoporosis and anti-resorptive drug treatment on trabecular structure. We then asked the question whether *preventive* treatment could preserve bone mass and structure on the long term.

METHODS

We incorporated our theory in a computational model. Starting from a conceptual morphology, representing bone tissue at the post-mineralized fetal stage, the modeling simulation was continued to morphological homeostasis, representing mature bone where only remodeling still occurred (Ruimerman, 2003). After this stage *disuse osteoporosis* was invoked by reducing the mechanical loading magnitude by 50%. In the resulting osteoporotic structure the osteoclastic activation frequency was reduced by 70% in order to mimic the effects of – therapeutic or *late* – anti-resorptive drug administration (Steiniche, 1991). To study the effects of *preventive* treatment, we repeated the simulation of inducing *disuse osteoporosis* and reduced osteoclastic activation prematurely, i.e. at the moment of reducing the loading magnitude.

RESULTS

Starting from the post-mineralized fetal stage, the simulation produced a mature trabecular structure, aligned to the external loads, in approximately 8 simulated years. After that stage no more significant morphological changes occurred. After 20 simulated years the analysis was discontinued (fig 1a-b).

Invoking mechanically induced *osteoporosis* resulted in loss of bone due to trabecular thinning and loss of connectivity (fig 1c, table 1) until finally homeostasis was restored. Simulated anti-resorptive drug administration (*late* treatment) in the osteoporotic

structure resulted in trabecular thickening but connectivity was not restored.

Simulated *preventive* anti-resorptive drug administration resulted in slower loss of bone tissue. Compared to *late* treatment, it did not preserve more bone mass on the long term. Trabecular connectivity however, was preserved (table 1).




Fig 1: a) Initial, b) homeostatic (mature) and c) osteoporotic trabecular structure.

	VF	Nett full turnover (years)	Tr.Th. (µm)	Reduction in number of trab (*)
Reference situation	0.192	3.9	183	-
Forces 50%	0.108	3.1	147	20
Late treatment	0.126	6.1	155	21
Preventive treatment	0.127	5.9	147	7

* Compared to the reference situation

Table 1: Morphological characteristics for the mature homeostatic (reference), osteoporotic (Forces 50%) and ARD-treated structures.

DISCUSSION

The simulations explain the structural developments observed in trabecular bone growth (modeling), adulthood (remodeling) and osteoporosis (Mosekilde, 1988). The effects of anti-resorptive drugs (*late* treatment) on bone mass were realistic as well (Liberman, 1995). Simulated *preventive* anti-resorptive drug administration reduced the rate of bone loss. Compared to *late* treatment it did not preserve bone mass on the long term. Trabecular connectivity, however, was preserved, which results in higher resistance to un-physiological - “error” - loads. The treatment increases tissue age with a risk of enhanced crack propagation.

REFERENCES

- Huiskes et al., *Nature* 405:704-706, 2000; Liberman et al., *New Engl. J. Med.* 333:1437-1443, 1995; Mosekilde et al., *Bone* 9: pp 247-250, 1988; Ruimerman et al., ORS, 2003; Steiniche et al., *Bone* 12: pp 155-163, 1991;